Synovial Chondromatosis and Chondrosarcoma: A Diagnostic Dilemma

Sperling, Brita L; Angel, Steven; Stoneham, Grant; Chow, Vance; McFadden, Andrew W.; Chibbar, Rajni

doi:10.1080/13577140310001607293

Cited by 46 publications

(46 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, both may present with pain, swelling and restricted movement of the affected joint with longstanding symptoms. Several authors speculate that a rapid deterioration of a longstanding clinical history or rapid recurrence after synoviectomy may indicate malignant transformation (31,34,53).…”

Section: Resultsmentioning

confidence: 99%

“…They also indicated that the only MRI criterion of malignancy was the invasion of the bone medullar canal. More recently, in 2003, Sperling et al (31) speculated that the under-expression of the BCL-2 (a cell survival marker) in SCH could be used as diagnostic immunohistochemical tool. Moreover, cytogenetic data can offer important information for the diagnosis and our understanding of the development of SCH from SC.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Synovial chondrosarcoma

Biazzo¹,

Confalonieri²

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Background: Synovial chondrosarcoma (SCH) is a very rare tumor arising in the intra-articular cavity. In the majority of literature reports it is described as a malignant transformation of a pre-existing synovial chondromatosis (SC). We reported a systematic review of primary and secondary SCH described in the literature with the aim to recollect data from different case-reports and case-series, trying to summarize general aspects of this very rare disease. Methods:We collected 42 abstracts in the form of case series and case reports, which reported 67 cases of SCH.Studies were taken into account only if they proved a histological diagnosis of SCH, either primary or secondary, with or without evidence of pre-existing SC.Results: The average age of SCH was 56.9 years, with prevalence for male sex. The average time of malignant transformation was 11.2 years. The most affected joint was the knee (47.7%), followed by hip (34.3%) and ankle (5.9%). SCH was described as de novo sarcoma only in 13 cases (19%). Surgery ended up with amputation in 59.7% of cases. Local recurrence rate was 28.3%. Conclusions:We concluded that prognosis of SCH is worse than conventional one and we speculated this is due to the difficult site of the tumor (intraarticular), diagnostic delay and inappropriate previous treatments. We consider that a rapid deterioration of a SC or rapid recurrence after synoviectomy should be considered suspicious of malignant transformation and should be treated in a reference center.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Synovial chondrosarcoma

Biazzo¹,

Confalonieri²

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…The most reliable histological sign consists of osseous permeation by cartilage with extension of cartilage matrix into intertrabecular spaces (4, 5, 7). A preliminary study suggests that reduced or absent expression of the immunohistochemical marker Bcl2 is associated with malignant transformation of chondromatosis (9).…”

Section: Discussionmentioning

confidence: 99%

Rapid Malignant Transformation of Primary Synovial Chondromatosis into Chondrosarcoma

Jonckheere

Shahabpour²,

Willekens³

et al. 2014

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

“…So far, the immunohistochemistry has not been of much use in differentiating these two conditions. Sperling et al 5 reported that a reduced or absent expression of bcl-2 may be associated with malignant transformation. Their results were in contradiction with the results of Bovee et al 14 who found that bcl-2 expression was significantly higher in low-grade synovial chondrosarcomas than in synovial chondromatosis.…”

Section: Discussionmentioning

confidence: 98%